524 related articles for article (PubMed ID: 37507595)
61. [Fixed combination of budesonide, formoterol, glycopyrronium for the treatment of severe COPD : Trixeo Aerosphere®].
Louis R; Bonhomme O; Heinen V; Nguyen D; Van Cauwenberge H; Corhay JL
Rev Med Liege; 2022 Apr; 77(4):244-248. PubMed ID: 35389009
[TBL] [Abstract][Full Text] [Related]
62. A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease.
Muraki M; Kunita Y; Shirahase K; Yamazaki R; Hanada S; Sawaguchi H; Tohda Y
BMC Pulm Med; 2021 Jan; 21(1):26. PubMed ID: 33441146
[TBL] [Abstract][Full Text] [Related]
63. EVELUT®: A Real-World, Observational Study Assessing Dyspnoea and Symptom Burden in COPD Patients Switched from LABA/ICS to LAMA/LABA or LAMA/LABA/ICS.
Buhl R; Dreher M; Mattiucci-Guehlke M; Emerson-Stadler R; Eckhardt S; Taube C; Vogelmeier CF
Adv Ther; 2023 Jul; 40(7):3263-3278. PubMed ID: 37256536
[TBL] [Abstract][Full Text] [Related]
64. Prescription Patterns of New Use of Fixed-Dose Combination Inhalers in Patients with Chronic Obstructive Pulmonary Disease: Long-Acting β2 Agonists Plus Long-Acting Muscarinic Antagonists versus Long-Acting β2 Agonists Plus Inhaled Corticosteroids.
Liao PA; Pan SW; Chen CY; Deng CY; Dong YH
Int J Chron Obstruct Pulmon Dis; 2023; 18():553-563. PubMed ID: 37069844
[TBL] [Abstract][Full Text] [Related]
65. Efficacy and Safety of Indacaterol/Glycopyrronium (IND/GLY) Versus Salmeterol/Fluticasone in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: The Chinese Cohort from the LANTERN Study.
Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Patalano F; Banerji D
COPD; 2016 Dec; 13(6):686-692. PubMed ID: 27715335
[TBL] [Abstract][Full Text] [Related]
66. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
[TBL] [Abstract][Full Text] [Related]
67. Which LABA/LAMA should be chosen in COPD patients in real life?
Sposato B; Petrucci E; Serafini A; Lena F; Lacerenza LG; Montagnani A; Alessandri M; Cresti A; Scala R; Rogliani P; Ricci A; Perrella A; Scalese M
Pulm Pharmacol Ther; 2021 Dec; 71():102076. PubMed ID: 34530132
[TBL] [Abstract][Full Text] [Related]
68. Risk Assessment of Acute Myocardial Infarction and Stroke Associated with Long-Acting Muscarinic Antagonists, Alone or in Combination, versus Long-Acting beta2-Agonists.
Rebordosa C; Plana E; Rubino A; Aguado J; Martinez D; Lei A; Daoud S; Saigi-Morgui N; Perez-Gutthann S; Rivero-Ferrer E
Int J Chron Obstruct Pulmon Dis; 2022; 17():1715-1733. PubMed ID: 35941901
[TBL] [Abstract][Full Text] [Related]
69. Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study.
Wedzicha JA; Zhong N; Ichinose M; Humphries M; Fogel R; Thach C; Patalano F; Banerji D
Int J Chron Obstruct Pulmon Dis; 2017; 12():339-349. PubMed ID: 28176893
[TBL] [Abstract][Full Text] [Related]
70. Cost-effectiveness of the fixed-dose combination tiotropium/olodaterol versus tiotropium monotherapy or a fixed-dose combination of long-acting β2-agonist/inhaled corticosteroid for COPD in Finland, Sweden and the Netherlands: a model-based study.
Hoogendoorn M; Corro Ramos I; Soulard S; Cook J; Soini E; Paulsson E; Rutten-van Mölken M
BMJ Open; 2021 Aug; 11(8):e049675. PubMed ID: 34348953
[TBL] [Abstract][Full Text] [Related]
71. Long-acting muscarinic antagonist versus long-acting β2 agonist/corticosteroid for moderate to severe chronic obstructive pulmonary disease patients: Exacerbation risk assessment.
Yang SN; Ko HK; Hsiao YH; Su KC; Chang YL; Huang HY; Perng DW; Chung MI
J Chin Med Assoc; 2019 Jun; 82(6):488-494. PubMed ID: 31180947
[TBL] [Abstract][Full Text] [Related]
72. Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy.
Moretz C; Hahn B; White J; Goolsby Hunter A; Essoi B; Elliott C; Ray R
Int J Chron Obstruct Pulmon Dis; 2020; 15():2715-2725. PubMed ID: 33149569
[TBL] [Abstract][Full Text] [Related]
73. Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids.
Asche CV; Leader S; Plauschinat C; Raparla S; Yan M; Ye X; Young D
Int J Chron Obstruct Pulmon Dis; 2012; 7():201-9. PubMed ID: 22500120
[TBL] [Abstract][Full Text] [Related]
74. Dual bronchodilation in COPD: lung function and patient-reported outcomes - a review.
Price D; Østrem A; Thomas M; Welte T
Int J Chron Obstruct Pulmon Dis; 2017; 12():141-168. PubMed ID: 28115839
[TBL] [Abstract][Full Text] [Related]
75. Stepwise management of COPD: What is next after bronchodilation?
Miravitlles M; Matsunaga K; Dreher M
Ther Adv Respir Dis; 2023; 17():17534666231208630. PubMed ID: 37936381
[TBL] [Abstract][Full Text] [Related]
76. Dual bronchodilation for the treatment of COPD: From bench to bedside.
Cazzola M; Page C; Rogliani P; Calzetta L; Matera MG
Br J Clin Pharmacol; 2022 Aug; 88(8):3657-3673. PubMed ID: 35514240
[TBL] [Abstract][Full Text] [Related]
77. Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β
Czira A; Requena G; Banks V; Wood R; Tritton T; Castillo CM; Yeap J; Wild R; Compton C; Rothnie KJ; Herth F; Quint JK; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2023; 18():643-659. PubMed ID: 37155496
[TBL] [Abstract][Full Text] [Related]
78. Recent advances in COPD disease management with fixed-dose long-acting combination therapies.
Bateman ED; Mahler DA; Vogelmeier CF; Wedzicha JA; Patalano F; Banerji D
Expert Rev Respir Med; 2014 Jun; 8(3):357-79. PubMed ID: 24802656
[TBL] [Abstract][Full Text] [Related]
79. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis.
Hertel N; Kotchie RW; Samyshkin Y; Radford M; Humphreys S; Jameson K
Int J Chron Obstruct Pulmon Dis; 2012; 7():183-99. PubMed ID: 22500119
[TBL] [Abstract][Full Text] [Related]
80. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study.
Suissa S; Dell'Aniello S; Ernst P
Lancet Respir Med; 2018 Nov; 6(11):855-862. PubMed ID: 30343028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
